Cargando…

Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol‐3‐kinase inhibitors: A systematic review and meta‐analysis of randomized controlled trials

BACKGROUND: Cutaneous adverse effects (AEs) are common following the phosphoinositide‐3‐kinase (PI3K) inhibitors treatment. We aim to estimate the incidence and risk of PI3K inhibitor‐related cutaneous AEs. METHODS: The protocol was submitted to the PROSPERO registry. We searched ClinicalTrials.gov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yushu, Ma, Zhuo, An, Zhuoling, Zhang, Yi, Feng, Xin, Yu, Xiaojia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	REVIEWS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939201/ https://www.ncbi.nlm.nih.gov/pubmed/35986570 http://dx.doi.org/10.1002/cam4.5153

Ejemplares similares

Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials
por: Zhang, Yi, et al.
Publicado: (2022)

Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System
por: Yang, Hui, et al.
Publicado: (2022)

Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway
por: Crowder, Robert J, et al.
Publicado: (2005)

Unlocking the Mechanisms of Cutaneous Adverse Drug Reactions: Activation of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway by EGFR Inhibitors Triggers Keratinocyte Differentiation and Polarization of Epidermal Immune Responses
por: Ondet, Thomas, et al.
Publicado: (2021)

Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia
por: Goncalves, Marcus D., et al.
Publicado: (2022)

Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma
por: Fang, Xiaosheng, et al.
Publicado: (2013)

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
por: Brana, Irene, et al.
Publicado: (2012)

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
por: Zhao, Wennan, et al.
Publicado: (2017)

Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors
por: Šála, Michal, et al.
Publicado: (2016)

Decoding kinase-adverse event associations for small molecule kinase inhibitors
por: Gong, Xiajing, et al.
Publicado: (2022)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
por: Apalla, Zoe, et al.
Publicado: (2021)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Development of selective inhibitors of phosphatidylinositol 3-kinase C2α
por: Lo, Wen-Ting, et al.
Publicado: (2022)

Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor
por: Starzyk, Tory, et al.
Publicado: (2021)

The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication
por: Delang, Leen, et al.
Publicado: (2012)

Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
por: Mohanavelu, Prahathishree, et al.
Publicado: (2021)

Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis
por: Zhao, Fangmin, et al.
Publicado: (2022)

The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
por: Owczarek, Witold, et al.
Publicado: (2017)

Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article
por: Chen, Chieh-Hsun, et al.
Publicado: (2022)

Phosphatidylinositol Kinases and Phosphatases in Entamoeba histolytica
por: Nakada-Tsukui, Kumiko, et al.
Publicado: (2019)

Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma
por: Yang, Hang, et al.
Publicado: (2015)

The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection
por: Nelson, Elizabeth A., et al.
Publicado: (2017)

Phosphatidylinositol-4-Phosphate 5-Kinases and Phosphatidylinositol 4,5-Bisphosphate Synthesis in the Brain
por: Volpicelli-Daley, Laura A., et al.
Publicado: (2010)

Efficacy of Phosphatidylinositol-3 Kinase Inhibitors in a Primary Mouse Model of Undifferentiated Pleomorphic Sarcoma
por: Kim, Suzy, et al.
Publicado: (2012)

Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
por: Chanprapaph, K., et al.
Publicado: (2014)

Metabolic adverse events of multitarget kinase inhibitors: a systematic review
por: Acitelli, Elisa, et al.
Publicado: (2023)

Inhibitors of Phosphatidylinositol 3′-Kinases Promote Mitotic Cell Death in HeLa Cells
por: Hou, Heli, et al.
Publicado: (2012)

Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
por: Shaker, Mohamed E., et al.
Publicado: (2023)

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis
por: Hu, Jiexuan, et al.
Publicado: (2021)

Pancreatic adverse events in patients treated with immune checkpoint inhibitors
por: Hana, Caroline, et al.
Publicado: (2023)

Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis
por: Lu, Wenchao, et al.
Publicado: (2023)

Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis
por: Kronick, Olivia, et al.
Publicado: (2023)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells
por: Baba, Atsushi, et al.
Publicado: (2013)

Corrigendum: Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib
por: Shaker, Mohamed E., et al.
Publicado: (2023)

Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome
por: Volpi, Stefano, et al.
Publicado: (2019)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells
Publicado: (1995)

Vemurafenib and cutaneous adverse events - report of five cases
por: Silva, Giselle de Barros, et al.
Publicado: (2015)

Management of immune-related cutaneous adverse events with dupilumab
por: Kuo, Alyce Mei-Shiuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3qjuca3j6n4a35joaqvtqk0do3